Insta
India Joins WHO’s ‘Solidarity Trials’ Of Anti-Ebola Remdesivir, Other Drugs Against Covid-19
World Health Organisation (WHO) (Pic Via WHO Website)
India has joined the World Health Organisation (WHO)'s solidarity trials for the drug Remdesivir which had shown promising results in the treatment of Covid-19 patients needing enhanced oxygen and ventilator support, reports Times of India.
Being a member of the WHO trials, India will be able to access the benefits which arise out of it, if and when the medication is established for the treatment of Covid-19 in clinical use. The clinical trials of the drug are however still to begin.
Remdesivir drug was developed to be effective in the fight against Ebola and has shown significant benefits for two-thirds of patients with severe symptoms during the use on a set of patients in the United States (US), Canada, Europe and Japan, who were able to thereafter get off oxygen and ventilator support.
The development was made public by the Indian Council of Medical Research (ICMR)'s Dr Raman Gangakhedkar during the Union Ministry of Health and Family Welfare (MoHFW)'s daily briefing on Monday (13 April). Meanwhile, it should be noted that the WHO's solidarity trials are also working to analyse the efficacy of other drugs against Covid-19.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
